SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
But mixed data and a previous failure provide reasons to be cautious.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.